Newsroom | 40462 results
Sorted by: Latest
-
Court Grants Final Approval to Roundup™ Class Settlement
ST. LOUIS--(BUSINESS WIRE)--Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy design...
-
Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement
SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement...
-
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the company will participate in the following investor conferences:Evercore 9th Annual Healthcare Conference at The Loews Coral Gables Hotel in Coral Gables, FL. Fireside chat on Tuesday, December 1, 2026, at 1:45pm ET.Piper Sandler 38th Annual Healthcare Conference at the Lotte New York Palace in New York, NY. Fire...
-
Ataraxis AI to Present Nine Studies at SABCS 2026
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, announced today that it will present nine studies at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark Phase III TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against legacy genomic assays. Ataraxi...
-
CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch....
-
Alterome Therapeutics Presents Preliminary Clinical Data from Ongoing Phase 1/1b Trial of ALTA3263 Demonstrating Antitumor Activity in KRAS-Mutant Colorectal and Pancreatic Cancers at the 38th EORTC-NCI-AACR Symposium
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers, today announced the presentation of the preliminary clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor, in adult patients with KRAS-mutant advanced...
-
Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
RAHWAY, N.J.--(BUSINESS WIRE)--TroFuse-015 Evaluating Sac-TMT Met Primary Endpoint of OS in 3rd-Line or Later Locally Adv. Unresectable or Metastatic Gastroesophageal Adenocarcinoma...
-
Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) platform for solid tumors offering personalized, ultra-sensitive detection of residual cancer. Built on Guardant’s Smart Platform, Reveal Ultra incorporates tumor-informed, patient-specific genomic alterations to provide one of the most advanced and actionable views of MRD. Validat...
-
Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a corporate update and operational progress conference call and webcast on Monday, November 30, 2026. The call is scheduled to take place at 8:00 a.m. EST. The conference call and webcast details, including dial-in information and webcast link, will be posted on the Investor Relations section of Summit's website, www.smmttx.com. The archived webcast will be available through the company's website after the call has conclu...
-
Polymedco Promotes Chris Mathews to Chief Executive Officer, Names John McDonough Executive Chairman of the Board
CORTLANDT MANOR, N.Y.--(BUSINESS WIRE)--Polymedco, a leader in diagnostic testing solutions dedicated to early disease detection, announced the promotion of Chris Mathews to Chief Executive Officer and John McDonough named as Executive Chairman of the Board of Directors. Together, the appointments strengthen Polymedco’s leadership as the company continues to expand access to its diagnostic technologies and advance its mission of catching colorectal cancer and heart attacks early, when they are...